Recombinant chimeric (primate/human) antibody expressed in CHO binding to human CD4/p55. Clenoliximab is a monoclonal antibody against CD4. It acts as an immunomodulator and has been investigated for the treatment of rheumatoid arthritis. The drug is a chimeric antibody from Macaca irus and Homo sapiens.
Figure 1 Fc receptor binding characteristics of keliximab and clenoliximab.
A, Keliximab-mediated adhesion of IFN-treated monocytic cell line (THP1) to CD4 fibroblast transfectants. Also shown is the inhibition of this CD4 mAb-mediated adhesion by sCD4 along with the effect of truncated form of keliximab. B, Comparison of IgG1 and IgG4 anti-CD4 mAbs in FcR-CD4-mediated cell-cell adhesion assay. Percent adhesion of THP-1 cells to CD4 T cells was calculated as: (fluorescence of test samples/total fluorescence) 100. Data points are the mean SEM of triplicate cultures.
Reddy, M. P., Kinney, C. A. S., Chaikin, M. A., Payne, A., Fishman-Lobell, J., Tsui, P.,... & Reff, M. (2000). Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. The Journal of Immunology, 164(4), 1925-1933.
Figure 2 Flow cytometric analysis.
A, Keliximab and clenoliximab-mediated adhesion of CD4 T cells to IFN-induced Fc receptor-expressing monocytes. Anti-CD4 mAbs serve as a bridge between the monocytes on the microtiter plates and fluorescent dye loaded SupT1-18 T cells. Percent binding of SupT1-18 cells to monocytes was calculated as in Fig. 4B (fluorescence of test samples/total fluorescence) 100. Data represent one of three experiments that showed identical results (15). B, Freshly isolated human monocytes were cultured for 36 h with 250 U/ml human IFN-, after which induction of Fc receptor expression was measured by staining with anti-human CD64-FITC, CD32-FITC, and CD16-FITC Abs. Flow cytometric analysis was performed using CellQuest software (Becton Dickinson).
Reddy, M. P., Kinney, C. A. S., Chaikin, M. A., Payne, A., Fishman-Lobell, J., Tsui, P.,... & Reff, M. (2000). Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. The Journal of Immunology, 164(4), 1925-1933.
Figure 3 Keliximab and clenoliximab induced CD4 and CD3 receptor modulation.
Shown are flow cytometric two-dimensional scatter plots of human PBMCs incubated with 100 ng/ml of keliximab or clenoliximab or medium without added Ab and dual stained for CD4 (OKT4) and CD3 markers after 24 h of culture.
Reddy, M. P., Kinney, C. A. S., Chaikin, M. A., Payne, A., Fishman-Lobell, J., Tsui, P.,... & Reff, M. (2000). Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. The Journal of Immunology, 164(4), 1925-1933.
Figure 4 Cytokine secretion profile.Animals were administered 1*10¹¹ particles of Ad-lacZ intratracheally in the presence or the absence of Clenoliximab (CD4 mAb), and splenocytes were harvested 14 days later for stimulation with adenovirus and analysis for secretion of cytokines.
IL-2, IFN-g, IL-4, and IL-10 were measured in serum by ELISA and plotted as picograms per milliliter. The results were obtained from pooled spleens of three to five mice, and the values shown are the mean 6 1 SD from three or four separate experiments. Supernatants were analyzed from cells treated with medium (f) or stimulated with Ad-lacZ (M). These analyses were performed with muCD4KO, HuCD4, or HuCD4 treated with Clenoliximab (CD4 mAb). p, p, 0.001, using Student's t test.
Chirmule, N., Truneh, A., Haecker, S. E., Tazelaar, J., Gao, G. P., Raper, S. E.,... & Wilson, J. M. (1999). Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a nondepleting CD4 antibody. The Journal of Immunology, 163(1), 448-455.
Figure 5 Cellular and humoral immune functions in HuCD4 mice treated with Clenoliximab (CD4 mAb).
This figure summarizes the T cell proliferative and humoral responses in HuCD4 mice treated with multiple doses of vector in the presence or the absence of Clenoliximab. A and B, Splenocytes obtained on various days were analyzed for adenovirus- and SEB-induced lymphoproliferative responses as described in Materials and Methods. Data are presented as the stimulation index, which is the incorporation of radioactivity in the presence of stimulator (i.e., adenovirus or SEB) over the incorporation of isotope when cells are incubated with medium alone. Analyses were performed on days 28, 60, and 90. A, Adenovirus-induced lymphoproliferation (LPR) responses; B, SEB-induced LPR responses. C and D, The humoral immune responses of animals that received multiple administrations of vector in the presence or the absence of Clenoliximab. C, Neutralizing Ab from serum; D, neutralizing Ab from BAL (both presented as reciprocal dilutions).
Chirmule, N., Truneh, A., Haecker, S. E., Tazelaar, J., Gao, G. P., Raper, S. E.,... & Wilson, J. M. (1999). Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a nondepleting CD4 antibody. The Journal of Immunology, 163(1), 448-455.
Figure 6 Treatment of HuCD4 mice with Clenoliximab prolongs transgene expression in mouse lung.
Animals were euthanized on days 4, 28, 60, and 90 (rows 1, 2, 3, and 4, respectively) and analyzed for expression of b-galactosidase by X-galactosidase histochemistry. Magni-
fication is 3200. The results are representative of one of six mice in each group.
Chirmule, N., Truneh, A., Haecker, S. E., Tazelaar, J., Gao, G. P., Raper, S. E.,... & Wilson, J. M. (1999). Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a nondepleting CD4 antibody. The Journal of Immunology, 163(1), 448-455.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-CD4 ADCC Recombinant Antibody (Clenoliximab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant chimeric (primate/human) antibody expressed in CHO binding to human CD4/p55. Clenoliximab is a monoclonal antibody against CD4. It acts as an immunomodulator and has been investigated for the treatment of rheumatoid arthritis. The drug is a chimeric antibody from Macaca irus and Homo sapiens.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-039 | Anti-Human CD4 Recombinant Antibody (Zanolimumab) | Neut, ELISA, IF, IP, FuncS, FC, IHC | IgG1 - kappa |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-107 | Anti-Human CD4 Recombinant Antibody (Cedelizumab) | IF, IP, Neut, FuncS, ELISA, FC, ICC | IgG4 - kappa |
TAB-161LC-S(P) | Anti-Human CD4 Recombinant Antibody scFv Fragment (gOKT4A-4) | ELISA | Humanized antibody |
TAB-161LC-F(E) | Anti-Human CD4 Recombinant Antibody Fab Fragment (gOKT4A-4) | ELISA | Humanized antibody |
TAB-168LC-F(E) | Anti-Human CD4 Recombinant Antibody Fab Fragment (TRX1) | ELISA | Humanized antibody |
TAB-171LC-F(E) | Human Anti-CD4 Recombinant Antibody; Fab Fragment (TAB-171LC-F(E)) | ELISA, SPR | Humanized Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-G078E | Anti-CD4 immunotoxin M-T151 (IgG)-PE | Cytotoxicity assay, Function study | |
AGTO-G078R | Anti-CD4 immunotoxin M-T151 (IgG)-RTA | Cytotoxicity assay, Function study |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-167LC | Anti-Human CD4 Recombinant Antibody (cM-T412) | ELISA, Inhib | Chimeric antibody (mouse/human) |
TAB-170LC | Human Anti-CD4 Recombinant Antibody (TAB-170LC) | ELISA, FC, ADCC, CDC, SPR | Chimeric antibody (rat/human) |
TAB-165LC-S(P) | Monkey Anti-CD4 Recombinant Antibody; scFv Fragment (TAB-165LC-S(P)) | FC, SPR, ELISA | Monkey scFv |
TAB-167LC-S(P) | Anti-Human CD4 Recombinant Antibody scFv Fragment (cM-T412) | ELISA | Chimeric antibody (mouse/human) |
TAB-170LC-S(P) | Rat Anti-CD4 Recombinant Antibody; scFv Fragment (TAB-170LC-S(P)) | ELISA, SPR | Rat scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-025LC | Recombinant Anti-Human CD4 Antibody (Fab glycosylation) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-351CQ | Mouse Anti-CD4 Recombinant Antibody (clone 10C12) | ELISA, WB, IF, Block | Mouse IgG1 |
NEUT-352CQ | Mouse Anti-CD4 Recombinant Antibody (clone 13B8.2) | Block, ELISA, FC, IHC-Fr, WB | Mouse IgG1, κ |
NEUT-355CQ | Mouse Anti-CD4 Recombinant Antibody (clone RPA-T4) | FC, CyTOF, Block, IHC | Mouse IgG1, κ |
NEUT-357CQ | Rat Anti-CD4 Recombinant Antibody (clone MAB0810) | Block, Depletion, Stim | Rat IgG2b |
NEUT-358CQ | Rat Anti-CD4 Recombinant Antibody (clone RM4-5) | FC, CyTOF, Depletion, Block, IHC | Rat IgG2a, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-353CQ | Mouse Anti-CD4 Recombinant Antibody (clone CBL976) | FC, Neut, IF, IHC | Mouse IgG1, κ |
NEUT-354CQ | Recombinant Mouse Anti-CD4 Antibody (CT-4) | Neut, FC, IHC, IHC-Fr, IHC-P, IP | IgG1, κ |
NEUT-356CQ | Mouse Anti-CD4 Recombinant Antibody (clone 3-4F4) | Neut, FC, IHC, IHC-Fr, IP, ICC | Mouse IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-0560 | Hi-Affi™ Rabbit Anti-CD4 Recombinant Antibody (clone DS560AB) | IHC-P | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
FAMAB-0054YC | Mouse Anti-CD4 Recombinant Antibody (clone M-T310) | Neut | Mouse IgG1, κ |
FAMAB-0055YC | Mouse Anti-CD4 Recombinant Antibody (clone M-T404) | Neut | Mouse IgG1, κ |
FAMAB-0056YC | Mouse Anti-CD4 Recombinant Antibody (clone M-T408) | Neut | Mouse IgG1, κ |
FAMAB-0057YC | Mouse Anti-CD4 Recombinant Antibody (clone M-T151) | Neut | Mouse IgG2a, κ |
FAMAB-0007-CN | Mouse Anti-CD4 Recombinant Antibody (clone CT4) | FC | Mouse IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
FAMAB-0048CQ-S(P) | Mouse Anti-CD4 Recombinant Antibody (clone Leu3a); scFv Fragment | ELISA, FC | Mouse scFv |
HPAB-0557-WJ-S(P) | Human Anti-CD4 Recombinant Antibody (clone TRX1); scFv Fragment | ELISA | Human scFv |
HPAB-0558-WJ-S(P) | Human Anti-CD4 Recombinant Antibody (clone 6G5); scFv Fragment | ELISA | Human scFv |
HPAB-0957WJ-S(P) | Human Anti-CD4 Recombinant Antibody (clone 4-91); scFv Fragment | ELISA | Human scFv |
HPAB-2112-FY-S(P) | Mouse Anti-CD4 Recombinant Antibody (clone MT15.1); scFv Fragment | Inhib | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0758-CN-F(E) | Human Anti-CD4 Recombinant Antibody (clone Variant B); Fab Fragment | ELISA, FC | Human Fab |
HPAB-0759-CN-F(E) | Human Anti-CD4 Recombinant Antibody (clone Variant D); Fab Fragment | ELISA, FC | Human Fab |
HPAB-0792-CN-F(E) | Mouse Anti-CD4 Recombinant Antibody (clone B4); Fab Fragment | ELISA | Mouse Fab |
HPAB-0793-CN-F(E) | Human Anti-CD4 Recombinant Antibody (clone chB4); Fab Fragment | ELISA | Chimeric (mouse/human) Fab |
HPAB-0794-CN-F(E) | Human Anti-CD4 Recombinant Antibody (clone dB4C7); Fab Fragment | ELISA | Chimeric (mouse/human) Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-039 | Afuco™ Anti-CD4 ADCC Recombinant Antibody (Zanolimumab), ADCC Enhanced | Neut, ELISA, IF, IP, FuncS, FC | ADCC enhanced antibody |
AFC-TAB-164 | Afuco™ Anti-CD4 ADCC Recombinant Antibody (Priliximab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-260 | Afuco™ Anti-CD4 ADCC Recombinant Antibody (Tregalizumab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF | ADCC enhanced antibody |
AFC-TAB-171 | Afuco™ Anti-CD4 ADCC Recombinant Antibody (Keliximab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC, IP | ADCC enhanced antibody |
AFC-TAB-107 | Afuco™ Anti-CD4 ADCC Recombinant Antibody (Cedelizumab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
There are currently no Customer reviews or questions for TAB-732. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.